IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Delisted

IMUC was delisted on the 16th of October, 2018.

27 hedge funds and large institutions have $405K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.

Holders
27
Holders Change
+7
Holders Change %
+35%
% of All Funds
0.62%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
2
Reduced
4
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Renaissance Technologies
1
Renaissance Technologies
New York
$254K 1,211,604 +133,200 +12%
Vanguard Group
2
Vanguard Group
Pennsylvania
$60K 285,154
WS
3
Wedbush Securities
California
$18K 86,530
Citadel Advisors
4
Citadel Advisors
Florida
$15K 69,746 -66,297 -49%
VF
5
Virtu Financial
New York
$15K 71,027 -53,168 -43%
TSS
6
Two Sigma Securities
New York
$13K 61,448 +61,448 New
UBS Group
7
UBS Group
Switzerland
$12K 58,540 +26,270 +81%
FAAS
8
First Allied Advisory Services
California
$8K 40,000
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$7K 32,871 +32,871 New
Invesco
10
Invesco
Georgia
$2K 10,992 -1,373 -11%
NFG
11
Next Financial Group
Texas
$1K 3,000 +3,000 New
RCAG
12
Rehmann Capital Advisory Group
Michigan
$14 69
APA
13
American Portfolios Advisors
New York
$1 5
Morgan Stanley
14
Morgan Stanley
New York
$0 113 -24 -18%
Barclays
15
Barclays
United Kingdom
$0 50
RE
16
RBC Europe
United Kingdom
$0 2
FANJ
17
Financial Architects (New Jersey)
New Jersey
$0 1
CAC
18
Certified Advisory Corp
Florida
$0 20
Wells Fargo
19
Wells Fargo
California
$0 250
TCM
20
Tradewinds Capital Management
Washington
$0 200
IA
21
IFP Advisors
Florida
$0 95
BlackRock
22
BlackRock
New York
$0 672
JCM
23
Jacobi Capital Management
Pennsylvania
$0 125
CFGS
24
Concourse Financial Group Securities
Alabama
AA
25
Ancora Advisors
Ohio
$0 50 +50 New